Edgewise Therapeutics, Inc.

EWTXSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1710072

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	$90.9M	$90.9M	$54.0M	$32.2M	$15.0M
Operating Expenses	$114.4M	$114.4M	$71.7M	$43.2M	$17.2M
Operating Income (Loss)	-$114.4M	-$114.4M	-$71.7M	-$43.2M	-$17.2M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$100.2M	—	—	—	—
Income Tax Expense (Benefit)	$4.0K	$0.00	$0.00	$0.00	$0.00
Net Income (Loss) Attributable to Parent	-$100.2M	-$100.2M	-$67.6M	-$42.8M	-$17.1M
Earnings Per Share, Basic	-$1.57	-$1.57	-$1.26	-$1.14	-$23.17
Earnings Per Share, Diluted	-$1.57	-$1.57	-$1.26	-$1.14	-$23.17

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$486.8M	$340.0M	$367.1M	$285.2M	$131.1M
Assets, Current	$475.5M	$327.0M	$357.0M	$283.8M	$129.6M
Cash and Cash Equivalents, at Carrying Value	$41.7M	$86.1M	$22.0M	$15.6M	$104.9M
Liabilities	$27.6M	$21.2M	$20.4M	$10.8M	$4.3M
Liabilities, Current	$23.9M	$16.8M	$16.6M	$10.5M	$4.3M
Accounts Payable, Current	$5.6M	$4.0M	$6.1M	$3.8M	$1.6M
Stockholders' Equity Attributable to Parent	$346.7M	$346.7M	$274.4M	-$33.4M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$91.9M	-$91.9M	-$52.6M	-$33.5M	-$14.6M
Net Cash Provided by (Used in) Investing Activities	$102.9M	$102.9M	-$70.6M	-$242.2M	-$24.4M
Net Cash Provided by (Used in) Financing Activities	$53.2M	$53.2M	$129.6M	$186.4M	$120.3M
Payments to Acquire Property, Plant, and Equipment	$5.7M	$5.7M	$5.5M	$668.0K	$203.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)